Türkiye'nin doğusunda warfarin yanıtı üzerine VKORC1-1639 G>A polimorfizminin etkisi

Also there was no difference between GA and AA gropus in terms of INR.Conclusion: In conclusion, our study verified the inter individual variability in warfarin maintenance dose due to VKORC1-1639 G>A polymorphism in patients living in east of Turkish.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: The aim of the present study was to investigate whether the VKORC1 -1639 G>A polymorphisms could determine differences in the warfarin dose required to maintain a therapeutic INR in patients living in east of Turkish.Methods: A total of 80 patients (45 female and 35 male) aged between 17 and 85 years (mean age 58.96±16.59 years) using warfarin for at least one month and presenting at Atatürk University Medical Faculty Outpatient Clinic between May 2009 and May 2010 were included in the study.

📊

Key Findings & Data:Patients underwent genotype investigations and carrier forms of VKORC1 -1639 variants; homozygous (AA), heterozygous (GA) and wild types (GG) were determined.Results: In AA and GA groups, daily warfarin maintenance doses were statistically significant lower than in GG (p=0.010 and p=0.016, respectively).

💡

Conclusion & Impact:Also there was no difference between GA and AA gropus in terms of INR.Conclusion: In conclusion, our study verified the inter individual variability in warfarin maintenance dose due to VKORC1-1639 G>A polymorphism in patients living in east of Turkish.

🔬Design:Research Article

📍Scope:2009 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the present study was to investigate whether the VKORC1 -1639 G>A polymorphisms could determine differences in the warfarin dose required to maintain a therapeutic INR in patients living in east of Turkish.Methods: A total of 80 patients (45 female and 35 male) aged between 17 and 85 years (mean age 58.96±16.59 years) using warfarin for at least one month and presenting at Atatürk University Medical Faculty Outpatient Clinic between May 2009 and May 2010 were included in the study. Patients underwent genotype investigations and carrier forms of VKORC1 -1639 variants; homozygous (AA), heterozygous (GA) and wild types (GG) were determined.Results: In AA and GA groups, daily warfarin maintenance doses were statistically significant lower than in GG (p=0.010 and p=0.016, respectively). There was no significant difference between AA and GA groups regarding to warfarin dose (p>0.05). INR values were higher in GA and AA groups than in GG group and differences were statistically significant (p=0.014 and p=0.016, respectively). Also there was no difference between GA and AA gropus in terms of INR.Conclusion: In conclusion, our study verified the inter individual variability in warfarin maintenance dose due to VKORC1-1639 G>A polymorphism in patients living in east of Turkish. In order to avoid serious bleeding events in warfarin therapy, prescription of warfarin should be done on an individual basis with consideration for the patient's genetic background.

Özet

Amaç: Çalışmanın amacı Türkiye'nin doğusunda yaşayan hastalarda, tedavi edici INR seviyesine ulaşmak için gerekli warfarin dozunun VKORC1 -1639 G>A polimorfizmine göre değişiklik gösterip göstermediğini tespit etmekti.Metod: Çalışma kapsamına Atatürk Üniversitesi Tıp Fakültesi İç Hastalıkları Polikliniği'ne Mayıs 2009 ve Mayıs 2010 yılları arasında yaşları 17-85 arasında olan (ortalama yaş 58.96±16.59 yıl) ve en az bir ay süre ile warfarin kullanan, 45'i kadın ve 35'i erkek, toplam 80 hasta alındı. VKORC1 -1639 G>A polimorfizmi için genetik araştırma yapıldı ve bu genin varyantları; homozigot (AA), heterozigot (GA) ve wild tip (GG) olması açısından değerlendirildi.Bulgular: Günlük warfarin idame dozu, AA ve GA grubunda GG grubundan istatistiksel olarak anlamlı düşüktü (sırasıyla p=0.004 ve p=0.017). AA ve GA grubu arasında warfarin dozu açısından anlamlı farklılık yoktu (p>0.05). GA ve AA gruplarında, INR değerleri GG grubuna göre daha yüksekti ve farklılıklar istatistiki olarak anlamlı idi (sırası ile p=0.014 ve p=0.016). Ayrıca INR değeri açısından GA ve AA grupları arasında farklılık yoktu.Sonuç: Sonuç olarak çalışmamız; Türkiye'nin doğusunda yaşayan hastalarda, VKORC1-1639 G>A polimorfizmi nedeni ile warfarin idame dozları arasında bireysel farklılık olduğunu doğruladı. Warfarin tedavisine bağlı oluşan şiddetli kanamaları önlemek için tedaviye başlamadan önce hastanın genetik yapısına göre kişiye özel warfarin dozunu belirlemek gerekir.

🔖

Cite This Article

GÜNDOĞDU, M., LALOĞLU, E., ERDEM, F., KİKİ, İ., ÇADIRCI, K., YILDIRIM, R., YILDIRIM, A. (2022). Türkiye'nin doğusunda warfarin yanıtı üzerine VKORC1-1639 G>A polimorfizminin etkisi. Türk Biyokimya Dergisi, Cilt: 40 - Sayı: 4, 271–274. https://ajindex.com/articles/621098

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108(4 suppl):352-9. stein PD, Alpert Js, Copeland J, Dalen JE, Goldman s, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108(4 suppl):371-9.
Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(1 suppl):8-21.
Loebstein R, Yonath H, Peleg D, Almog s, Rotenberg M, et al. Interindividual variability in sensitivity to warfarin--Nature or nurture? Clin Pharmacol Ther 2001; 70(2):159-64.
Landefeld Cs, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95(3):315-28.
Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg Js. Clinical risk factors and timing of recurrent venous thrombo- embolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000; 160(22):3431-6.
Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 1985; 76(5):1879-84.
Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, stafford DW. Identi- fication of the gene for vitamin K epoxide reductase. Nature 2004; 427(6974):541-4.
D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, santacroce R, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2):645-9.
Rost s, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427(6974):537-41. H Tashiro Y, sakawa s, Moriwaki H, Akimoto T. Effect of VKORC1-1639 G> cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427:537-41.
Rathore ss, Agarwal sK, Pande s, Mittal T, Mittal B. The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study. Indian J Hum Genet 2011; 17 suppl 1:s54-7. Yoshizawa M, Hayashi H, Tashiro Y, sakawa s, Moriwaki H, et al. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 2009; 124(2):161-6. Zhu Y, shennan M, Reynolds KK, Johnson NA, Herrnberger MR, et al. Estimation of warfarin main